Comparison of HbA1c, Uric Acid/HDL-C ratio, and Electroneuromyography (ENMG) results in patients with Type 2 Diabetes Mellitus

Buket Özkara Yılmaz; Betül Özenç; Derya Bayrak; Pelin Yenilmez Yeşildaş; Erman Altunışık

doi:10.26900/hsq.2845

Authors

Buket Özkara Yılmaz Gaziantep City Hospital / Türkiye 0000-0002-1033-7737
Betül Özenç Gaziantep City Hospital / Türkiye 0000-0003-3674-7643
Derya Bayrak Gaziantep City Hospital / Türkiye 0009-0007-2501-3982
Pelin Yenilmez Yeşildaş Gaziantep City Hospital / Türkiye 0009-0001-7454-9309
Erman Altunışık Gaziantep City Hospital / Türkiye 0000-0002-5996-2090

10.26900/hsq.2845

Abstract

This study aims to compare the uric acid/HDL-C ratio and electroneuromyography (ENMG) results in patients with type 2 diabetes mellitus (T2DM) and to investigate whether these parameters differ in the presence or absence of diabetic peripheral neuropathy (DPN). Additionally, it evaluates the potential of HbA1c and the uric acid/HDL-C ratio as biomarkers for diagnosing DPN. This study was carried out retrospectively in the Neurology Clinic of Gaziantep City Hospital. The participants included 50 T2DM patients diagnosed with DPN through ENMG, 50 Type 2 DM patients without DPN, and 50 healthy controls. Demographic data, biochemical parameters (uric acid, HDL cholesterol, HbA1c), and ENMG results were analyzed. Intergroup comparisons and correlation analyses were performed. No significant differences in the uric acid/HDL-C ratio were observed among T2DM patients with DPN, those without DPN, and healthy controls. Moreover, the correlation between the uric acid/HDL-C ratio and ENMG results was found to be limited. The present study does not support the use of the uric acid/HDL-C ratio for neuropathy diagnosis, indicating the need for further research.

Keywords:

Uric acid HDL ratio HbA1c diabetic polyneuropathy

Downloads

Download data is not yet available.

References

Tesfaye S, Selvarajah D. Diabetic peripheral neuropathy: Explanatory factors and clinical relevance. Diabetes Res Clin Pract. 2012;96(3):214-23. doi: 10.1016/j.diabres.2011.12.013.

Kosekli MA, Aktas G. Serum uric acid to HDL cholesterol ratio is associated with diabetic control in new onset type 2 diabetic population. Acta Clin Croat. 2023;62(2):277-82. doi: 10.20471/acc.2023.62.02.14.

Isaka Y, Takabatake Y, Takahashi A, Saitoh T, Yoshimori T. Hyperuricemia-induced inflammasome and kidney diseases. Nephrol Dial Transplant. 2016;31(6):890-6. doi: 10.1093/ndt/gfv050.

Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H, et al. Clinical outcome of hyperuricemia in IgA nephropathy: A retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012;35(3):153-60. doi: 10.1159/000331453.

Cheng Y, Zhang H, Zheng H, Yin H, Wang Y, Wang H, et al. Association between serum uric acid/HDL-cholesterol ratio and chronic kidney disease: A cross-sectional study based on a health check-up population. BMJ Open. 2022;12(12):e066243. doi: 10.1136/bmjopen-2022-066243.

Han X, Tan X, Liu M, Wei Y, He A, Pan Y, et al. Association between serum uric acid/high-density lipoprotein cholesterol ratio and hypertension among reproductive-aged women. J Health Popul Nutr. 2023;42(1):123. doi: 10.1186/s41043-023-00472-3.

Xuan Y, Zhang W, Wang Y, Wang B, Xia F, Zhang K, et al. Association between uric acid to HDL cholesterol ratio and diabetic complications in men and postmenopausal women. Diabetes Metab Syndr Obes. 2023;16:167-77. doi: 10.2147/DMSO.S387726.

She D, Xu W, Liu J, Zhang Z, Fang P, Li R, et al. Serum uric acid to creatinine ratio and risk of metabolic syndrome in patients with overweight/obesity. Diabetes Metab Syndr Obes. 2023;16:3007-17. doi: 10.2147/DMSO.S418689.

Uzeli U, Doğan AG. The relationship between diabetic neuropathy and uric acid/high-density lipoprotein ratio in patients with type 2 diabetes mellitus. Cureus. 2023;15(9):e45151. doi: 10.7759/cureus.45151.

Zhen R, Wang S, Chen S. The relationship between UA/HDL and diabetic peripheral neuropathy: A cross-sectional analysis. Diabetes Metab Syndr Obes. 2024;17:969-80. doi: 10.2147/DMSO.S447809.

S Singh R, Sharma S, Kaur P. Diabetic neuropathy: An update on its clinical significance. J Diabetes Res. 2014;2014:654193. doi: 10.1155/2014/654193.

Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-54. doi: 10.2337/dc16-2042.

Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Diabetic neuropathy: An update on protein kinase C activation and targets for therapy. Diabetes Care. 2009;32(7):1476-82. doi: 10.2337/dc08-2174.

Vincent A, Sussex E, Hutton M, Unwin N, Alberti KG. Diabetes-related neuropathies: Epidemiology and treatment. BMJ. 2009;339:b393. doi: 10.1136/bmj.b393.

Joosten LAB, Crisan TO, Bjornstad P, Johnson RJ. Asymptomatic hyperuricemia: A silent activator of the innate immune system. Nat Rev Rheumatol. 2020;16(2):75-86. doi: 10.1038/s41584-019-0334-3.

Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the RENAAL trial. Hypertension. 2011;58(1):2-7. doi: 10.1161/HYPERTENSIONAHA.111.171488.

Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729-41. doi: 10.1097/HJH.0000000000000701.

Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced peripheral nervous system repair in diabetic neuropathy using phosphoinositide 3-kinase/Akt signaling. Diabetes Care. 2012;35(7):1374-80. doi: 10.2337/dc11-2202.

Feldman EL. Oxidative stress and diabetic neuropathy: A new understanding of an old problem. J Clin Invest. 2003;111(4):431-3. doi: 10.1172/JCI17862.

Liu Z, Hu Y, Chen J, Wang J, Zhou Y, Tang J, et al. Role of chronic inflammation in diabetic neuropathy. Diabetes Obes Metab. 2019;21(4):927-36. doi: 10.1111/dom.13607.

Fayazi HS, Faramarzi M, Pakzad R, Rezaei N. The relation between serum uric acid levels and diabetic peripheral neuropathy. BMC Endocr Disord. 2022;22:53. doi: 10.1186/s12902-022-00952-5.

Bazmandegan G, Dehghani MH, Karimifard M, Kahnooji M, Balaee P, Zakeri MA, et al. Uric acid to HDL ratio: A marker for predicting incidence of metabolic syndrome in patients with type II diabetes. Nutr Metab Cardiovasc Dis. 2024;34(4):1014-20. doi: 10.1016/j.numecd.2023.12.022.

Balci SB, Atak BM, Duman T, Ozkul FN, Aktas G. A novel marker for prediabetic conditions: Uric acid-to-HDL cholesterol ratio. Bratisl Lek Listy. 2024;125(3):145-8. doi: 10.4149/BLL_2023_130.

Cascio MA, Mukhdomi T. Small fiber neuropathy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. PMID:35881752. Available from: https://pubmed.ncbi.nlm.nih.gov/35881752/. (Accessed on Sep 13, 2025).

Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5:41. doi: 10.1038/s41572-019-0092-1.